PYPD News and Press, PolyPid Ltd. From 03/28/23

2023-03-28 16:25:18 ET PolyPid ( NASDAQ: PYPD ) said Tuesday it commenced an underwritten public offering of its ordinary shares. In addition, PolyPid intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares. ...

PETACH TIKVA, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that it has commenced an underwritten public offering of its...

PolyPid Ltd (PYPD) Q4 2022 Earnings Conference Call February 08, 2023, 08:30 ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO Ori Warshavsky - COO, US Jonny Missulawin - SVP, Finance Conference Call Participants Brandon Fol...

PolyPid press release ( NASDAQ: PYPD ): Q4 GAAP EPS of -$0.32 beats by $0.07 . As of December 31, 2022, the company had cash and cash equivalents and deposits in the amount of $12.6M, compared to $32.2M at December 31, 2021. PolyPid expects that this cash ba...

Following Positive Communication with the FDA , Regulatory Pathway Clarified for D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 20 23 into Ongoing SH...

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 fin...

Are Cheap Penny Stocks Worth It? If you’re new to trading penny stocks , you may ask yourself, “Are they worth it?” I can confidently say…it depends. All jokes aside, how you approach the stock market today and your taste for risk will determine a lot of the an...

• Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA • FDA Acknowledged that SHIELD I Pre-specified Subgroup Results May Provide Supportive Evidence and Proposed that Current SHIELD II Trial Could Potentially Serv...

D-PLEX 100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care Results Consistent with SHIELD I Phase 3 Post-hoc Analysis Demonstrating Significant Primary Endpoint Reduction in Patients with One...

Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the ...